Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746262 · ClinicalTrials.gov registry record
Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 40
- Enrollment target
NCT03746262 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants.
The verdict
NCT03746262 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate a blood test to measure circulating tumor DNA (ctDNA). It is hypothesized that ctDNA may identify patients who can be considered for additional therapy. 40 People with non-metastatic non-small cell lung cancer will be asked to take part in this study. Participants will have approximately 3 teaspoons of blood withdrawn from a vein at three different times. These times will be before primary treatment (either surgery or radiation therapy), 1 month after primary treatment, and 4 months after primary treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-05-13 |
| Est. Completion | 2018-08-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746262
The ClinicalTrials.gov registry entry for NCT03746262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03746262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03746262 about?
NCT03746262 is a clinical study titled "Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer". The purpose of this research study is to evaluate a blood test to measure circulating tumor DNA (ctDNA). It is hypothesized that ctDNA may identify patients who can be considered for additional therapy. 40 People with non-metastatic non-small cell lung cancer will be asked to take part in this study...
What is the current status of trial NCT03746262?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-05-13. Estimated completion is 2018-08-10.
Who is sponsoring clinical trial NCT03746262?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.